{"meta":{"query_hash":"21bfcc07159b","filters":{"venue":"Clinical Lymphoma"},"cohort_total":7,"direct_labels_cover":0,"predictions_cover":7,"exported":7,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/21bfcc07159b","api":"https://metacan.xera.ac/api/v1/cohort?venue=Clinical+Lymphoma"},"results":[{"id":"W1974738398","doi":"10.3816/clm.2005.n.030","title":"A Randomized Phase III Study of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin as Salvage Chemotherapy Followed by Posttransplantation Rituximab Maintenance Therapy Versus Observation for Treatment of Aggressive B-Cell and T-Cell Non-Hodgkin's Lymphoma","year":2005,"lang":"en","type":"article","venue":"Clinical Lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Salvage therapy; Etoposide; Internal medicine; Oncology; Vincristine; Gemcitabine; Cytarabine; Carboplatin; Febrile neutropenia; Surgery; Chemotherapy; Rituximab; Neutropenia; Cyclophosphamide; Cisplatin; Lymphoma","score_opus":0.045795418080093964,"score_gpt":0.36480908885507635,"score_spread":0.3190136707749824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974738398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98967314,0.0023548438,0.00065372256,0.00071751553,0.0009940104,0.0033671735,0.0006471946,0.00009566203,0.0014967913],"genre_scores_gemma":[0.98668855,0.0018453404,0.0017409659,0.0013080856,0.00084096286,0.0039512897,0.00092367386,0.000045926157,0.002655166],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9986112,0.0008098224,0.0000781478,0.00024163403,0.000075098564,0.00018405722],"domain_scores_gemma":[0.99655885,0.0011812906,0.00054503506,0.0003664668,0.00014689271,0.0012014459],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032342917,0.0023852899,0.005769566,0.0006920897,0.00070242374,0.0017564921,0.0020961193,0.002523386,0.0060341973],"category_scores_gemma":[0.0035452533,0.0012102091,0.0022444127,0.0007967151,0.0029226812,0.0020009999,0.0006738526,0.00654471,0.0015302313],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9882774,0.0063580642,0.00018149034,0.0000967367,0.00029945964,0.000015393714,0.000029607374,0.00015566684,0.0007263187,0.00005537307,0.00019143059,0.0036130736],"study_design_scores_gemma":[0.9526382,0.04602233,0.00050296646,0.000009384059,0.00020746855,0.000014274948,0.00001554728,0.00018234403,0.00014793436,0.00008996664,0.0001624614,0.000007100815],"about_ca_topic_score_codex":0.0017001736,"about_ca_topic_score_gemma":0.0031702784,"teacher_disagreement_score":0.0060341973,"about_ca_system_score_codex":0.0017098237,"about_ca_system_score_gemma":0.001899512,"threshold_uncertainty_score":0.020186424},"labels":[],"label_agreement":null},{"id":"W1983990351","doi":"10.3816/clm.2003.n.024","title":"Primary Adrenal Lymphoma","year":2003,"lang":"en","type":"review","venue":"Clinical Lymphoma","topic":"Adrenal and Paraganglionic Tumors","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Lymphoma; Incidence (geometry); Disease; Regimen; Adrenal insufficiency; Chemotherapy; Radiation therapy; Internal medicine; Oncology; Surgery","score_opus":0.12187550382528436,"score_gpt":0.420515326986854,"score_spread":0.2986398231615697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983990351","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00070269185,0.99512285,0.0001988004,0.0002469891,0.0002814698,0.000009187862,0.00003848728,0.00001995902,0.003379615],"genre_scores_gemma":[0.010520107,0.98572946,0.00027982384,0.0007725587,0.0005878883,0.000009948261,0.0001258482,0.000004058445,0.0019702604],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99979717,0.000034708468,0.000037732283,0.00004781385,0.000054798355,0.000027772177],"domain_scores_gemma":[0.9997013,0.000112612724,0.00007373063,0.000016283479,0.000062196465,0.000033776243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025460898,0.00083417207,0.0013630152,0.0029103858,0.0002180264,0.0010098158,0.00055698404,0.00061829516,0.005174482],"category_scores_gemma":[0.0009867789,0.00024674492,0.0003220746,0.003379817,0.00043012085,0.0012923884,0.00059689174,0.0008162297,0.0016752445],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000101920145,0.00004211602,0.0020321629,0.012743694,0.000105370964,0.006464309,0.000078614525,0.0002834254,0.0016881855,0.0006811178,0.0430003,0.9327788],"study_design_scores_gemma":[0.00011513874,0.00014576668,0.008602371,0.00960189,0.0008969363,0.09996064,0.0003135792,0.0002232161,0.0012072377,0.0013365108,0.8775567,0.000040023344],"about_ca_topic_score_codex":0.0015136848,"about_ca_topic_score_gemma":0.0035600234,"teacher_disagreement_score":0.005174482,"about_ca_system_score_codex":0.0006112622,"about_ca_system_score_gemma":0.0008859277,"threshold_uncertainty_score":0.017310381},"labels":[],"label_agreement":null},{"id":"W1994225339","doi":"10.3816/clm.2003.n.019","title":"Lymphomas and Oncolytic Virus Therapy","year":2003,"lang":"en","type":"review","venue":"Clinical Lymphoma","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; Calgary Laboratory Services; University of Alberta; University of Calgary","funders":"","keywords":"Oncolytic virus; Viral therapy; Virology; Lymphoma; Virus; Cancer therapy; Medicine; Cancer; Immunology; Coronavirus disease 2019 (COVID-19); Internal medicine; Disease; Infectious disease (medical specialty)","score_opus":0.11932318518071762,"score_gpt":0.44319979133702225,"score_spread":0.32387660615630465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994225339","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009253256,0.9970362,0.00036460688,0.00031068525,0.00051959226,0.000007761307,0.0000104573355,0.000014081119,0.0016442029],"genre_scores_gemma":[0.0009037672,0.9956807,0.00048200108,0.00042075478,0.00037420986,0.00001895605,0.00003305978,0.0000037058317,0.0020828086],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998068,0.000039755567,0.000019498508,0.00003053018,0.00007850049,0.000024863195],"domain_scores_gemma":[0.99976164,0.00012076792,0.000024024359,0.000011382631,0.00005976399,0.00002242163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009327236,0.0012149464,0.0016250212,0.0022193717,0.0003739182,0.0013031772,0.0012451184,0.0018115375,0.0028311266],"category_scores_gemma":[0.00074312126,0.00036350533,0.00041793863,0.0023833003,0.00087278575,0.0014809408,0.0006611834,0.0030729892,0.0024831565],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016053773,0.00013446859,0.00012639507,0.005177781,0.000052959876,0.00040577663,0.000051045583,0.00067653274,0.0030963428,0.0075987186,0.05827723,0.9242422],"study_design_scores_gemma":[0.000046754605,0.00005765874,0.00017382315,0.00082897686,0.000046915,0.0010709296,0.000025438057,0.000099844896,0.00074897707,0.0017718137,0.9951192,0.000009825528],"about_ca_topic_score_codex":0.0015531398,"about_ca_topic_score_gemma":0.003143057,"teacher_disagreement_score":0.0028311266,"about_ca_system_score_codex":0.0013448232,"about_ca_system_score_gemma":0.001150013,"threshold_uncertainty_score":0.009757459},"labels":[],"label_agreement":null},{"id":"W2079316702","doi":"10.3816/clm.2005.n.010","title":"Potential Impact of a Single Nucleotide Polymorphism in the Hyaluronan Synthase 1 Gene in Waldenström's Macroglobulinemia","year":2005,"lang":"en","type":"article","venue":"Clinical Lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute","keywords":"RNA splicing; Single-nucleotide polymorphism; Hyaluronan synthase; Gene; Biology; Intron; Genetics; Molecular biology; Genotype; RNA","score_opus":0.03790136286088836,"score_gpt":0.37230771499822624,"score_spread":0.3344063521373379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079316702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99811256,0.0006493983,0.00016572888,0.00036615084,0.000036721653,0.000004506641,0.00006986166,0.0000059322347,0.0005891273],"genre_scores_gemma":[0.99958295,0.00008292287,0.000066295914,0.00006894086,0.00004196431,0.0000016213119,0.00002837152,0.0000019992367,0.00012498253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992513,0.00039623948,0.000068935995,0.00008459927,0.00010697002,0.00009189569],"domain_scores_gemma":[0.9973042,0.0019309289,0.00030259692,0.000055568973,0.00011573762,0.00029092218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007709339,0.00053869345,0.00040723404,0.0010855829,0.00053293287,0.00048782062,0.0003878919,0.0011163551,0.0017228599],"category_scores_gemma":[0.0039217765,0.00016023475,0.00048625984,0.00073796883,0.0005965121,0.0002509675,0.00023050739,0.0006274102,0.00020925027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057525914,0.0004901325,0.908753,0.00009166107,0.00052576873,0.024636764,0.00033235722,0.0009914102,0.0404225,0.0008284533,0.00036662628,0.016808819],"study_design_scores_gemma":[0.0002934061,0.0016273105,0.96885467,0.000040462033,0.0010515426,0.015224868,0.00037420145,0.003578738,0.0066997753,0.0011635289,0.0010525229,0.0000390012],"about_ca_topic_score_codex":0.0016003593,"about_ca_topic_score_gemma":0.0012593481,"teacher_disagreement_score":0.0017228599,"about_ca_system_score_codex":0.00024138993,"about_ca_system_score_gemma":0.00040977506,"threshold_uncertainty_score":0.0057635903},"labels":[],"label_agreement":null},{"id":"W2090941758","doi":"10.3816/clm.2005.n.028","title":"ABVD, the Stanford V Regimen, and BEACOPP for Hodgkin's Lymphoma: What Should an Oncologist Do?","year":2005,"lang":"en","type":"review","venue":"Clinical Lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"ABVD; Medicine; Vincristine; Regimen; Vinblastine; Dacarbazine; Bleomycin; Prednisone; Etoposide; Internal medicine; Oncology; Hodgkin's lymphoma; Lymphoma; Chemotherapy; Cyclophosphamide","score_opus":0.2624196302931387,"score_gpt":0.49752479171567293,"score_spread":0.23510516142253424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090941758","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009340874,0.9990103,0.000029777542,0.00037809223,0.00012900171,0.0000031190004,0.000010992051,0.000003724211,0.00034154527],"genre_scores_gemma":[0.00064092816,0.9984218,0.00011905986,0.000448095,0.00012587897,0.000004314203,0.000024123583,9.1074355e-7,0.00021497055],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998128,0.000044816457,0.000037068323,0.000026742888,0.00006393883,0.000014770093],"domain_scores_gemma":[0.9996371,0.00018178033,0.00007017271,0.000008460921,0.000071923736,0.000030491972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072660076,0.00060646055,0.0025584714,0.0013086007,0.000255461,0.0007895228,0.0012170926,0.001086039,0.0024371836],"category_scores_gemma":[0.0010599293,0.0002754826,0.0006985219,0.0018997433,0.00035531074,0.0010326407,0.00035885806,0.0017664991,0.0009438535],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019123023,0.000051815932,0.00022261296,0.0171516,0.00022636846,0.00015853754,0.000028075494,0.00023340453,0.00032113853,0.00069025974,0.045186322,0.9355386],"study_design_scores_gemma":[0.00034385742,0.00030606304,0.003160167,0.015901778,0.001197263,0.0022018356,0.00012528429,0.00015988066,0.0002526638,0.0014776845,0.97483724,0.000036205965],"about_ca_topic_score_codex":0.0027281914,"about_ca_topic_score_gemma":0.0082597695,"teacher_disagreement_score":0.0027281914,"about_ca_system_score_codex":0.00063573144,"about_ca_system_score_gemma":0.0012155755,"threshold_uncertainty_score":0.008153141},"labels":[],"label_agreement":null},{"id":"W2092788376","doi":"10.3816/clm.2002.s.006","title":"Acute and Long-Term Toxicities Associated with Gemtuzumab Ozogamicin (Mylotarg®) Therapy of Acute Myeloid Leukemia","year":2002,"lang":"en","type":"review","venue":"Clinical Lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Gemtuzumab ozogamicin; Myeloid leukemia; Calicheamicin; Medicine; Leukemia; Pharmacology; Oncology; Internal medicine; CD33; Biology; Stem cell","score_opus":0.07021262687105202,"score_gpt":0.36695139610792527,"score_spread":0.29673876923687326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092788376","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008408959,0.9983998,0.00009845513,0.00006772887,0.00004240872,0.000007799209,0.000022217982,0.0000044547473,0.00051620684],"genre_scores_gemma":[0.0034665929,0.9956424,0.00022105346,0.00014426137,0.00005062626,0.000010577205,0.00004867389,0.0000011393917,0.0004146241],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9998672,0.000034470482,0.000028849934,0.000018920824,0.000042002917,0.000008559655],"domain_scores_gemma":[0.99979943,0.00009320495,0.000061804734,0.0000044350986,0.00003119758,0.000009836207],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047760297,0.00049596664,0.0014847189,0.0008504753,0.00014575662,0.000453536,0.00063652993,0.00041544507,0.0016058589],"category_scores_gemma":[0.00049070205,0.00015162375,0.0004859994,0.0013231107,0.0001692009,0.0004384082,0.00024245004,0.0005040726,0.00040874895],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003161187,0.00006630861,0.0004357108,0.025710637,0.00028729462,0.00030355185,0.000046187422,0.00025216214,0.0015229019,0.00041428366,0.007450509,0.9631944],"study_design_scores_gemma":[0.0005279433,0.0011672032,0.011073888,0.0111359805,0.003317979,0.008799763,0.0001592472,0.00027188583,0.0031054835,0.00089286524,0.95950615,0.00004158183],"about_ca_topic_score_codex":0.0008791952,"about_ca_topic_score_gemma":0.0029249792,"teacher_disagreement_score":0.0016058589,"about_ca_system_score_codex":0.00038046078,"about_ca_system_score_gemma":0.00056382094,"threshold_uncertainty_score":0.0053721666},"labels":[],"label_agreement":null},{"id":"W2102070406","doi":"10.3816/clm.2005.n.002","title":"Origins of Waldenström's Macroglobulinemia: Does It Arise from an Unusual B-Cell Precursor?","year":2005,"lang":"en","type":"review","venue":"Clinical Lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; Canada Research Chairs","keywords":"Immunoglobulin class switching; Somatic hypermutation; Waldenstrom macroglobulinemia; Immunoglobulin D; Macroglobulinemia; B cell; Biology; Immunoglobulin M; CD40; Cytidine deaminase; Monoclonal gammopathy of undetermined significance; Immunology; Molecular biology; Antibody; Monoclonal; Genetics; Monoclonal antibody; Immunoglobulin G; Multiple myeloma; Cytotoxic T cell; Lymphoma","score_opus":0.09611683324481807,"score_gpt":0.4676728339755265,"score_spread":0.37155600073070844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102070406","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025020246,0.9986796,0.00008093601,0.0003803779,0.00011326885,0.0000014873496,0.0000052188557,0.0000028764282,0.00048611188],"genre_scores_gemma":[0.001903693,0.9970612,0.00014942627,0.00031861616,0.00032876775,0.0000024462136,0.000016812508,0.0000010501595,0.0002179932],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99980956,0.000047644608,0.00003513666,0.000038133247,0.000044849025,0.000024681518],"domain_scores_gemma":[0.9993327,0.00037603153,0.000100574696,0.000024580624,0.00011959075,0.000046443507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007388284,0.0006679619,0.0015523569,0.0019545197,0.00028005848,0.0013189487,0.001056245,0.0018799369,0.0018456357],"category_scores_gemma":[0.0013408286,0.00034521273,0.00037890708,0.0018339342,0.0010411186,0.002266289,0.00064558,0.0016416322,0.0010225388],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020930477,0.00007004891,0.003666513,0.01050095,0.00012993414,0.009157759,0.00024377524,0.0003004229,0.0031701853,0.0070731537,0.025003782,0.94047415],"study_design_scores_gemma":[0.000056096247,0.00007001707,0.003835701,0.0041899034,0.00023316263,0.040075723,0.00034241524,0.00010034342,0.0009005966,0.0045684804,0.94559354,0.000033897555],"about_ca_topic_score_codex":0.0010176018,"about_ca_topic_score_gemma":0.0013648525,"teacher_disagreement_score":0.0019545197,"about_ca_system_score_codex":0.0007365998,"about_ca_system_score_gemma":0.0013394585,"threshold_uncertainty_score":0.0061742663},"labels":[],"label_agreement":null}]}